RecruitingNot ApplicableNCT07415018
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
Sponsor
M.D. Anderson Cancer Center
Enrollment
40 participants
Start Date
Jun 10, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Gadavist, a procedure called MRI Scan, and others for people with leptomeningeal disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREMRI Scan
Given during standard of care
DRUGVUEWAY
Given by IV
DRUGGadavist
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07415018
Related Trials
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
NCT076949861 location
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT024226413 locations
Non Interventional German Leptomeningeal Disease Register
NCT061460107 locations
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT058097523 locations
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT045885452 locations